C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Subscribe To Our Newsletter & Stay Updated
